SunTrust Robinson Humphrey downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Neutral with a price target of $33 (unchanged).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $34.63 yesterday.